Skip to content

Summative Usability Study of CEREBO® - a Non Invasive Intracranial Hemorrhage Detector

Summative Usability Study of a Novel Device - CEREBO® for Non Invasive Detection of Intracranial Haemorrhage

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05340127
Enrollment
10
Registered
2022-04-21
Start date
2022-04-20
Completion date
2023-01-31
Last updated
2022-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Usability

Keywords

Ease of Use, Ease of learning, Satisfaction

Brief summary

Traumatic brain injury is one of the most common reasons for visits to the Emergency Department. More than 90% of patients who have suffered from head trauma present with a mild traumatic brain injury. Most of these patients do not present any symptom at the time of diagnosis thus delaying the detection. CEREBO®, a non-invasive, portable, rapid, point-of-care intracranial haemorrhage detector can avoid delayed detection by decreasing the time from injury to the initial CT scan. The study aims at assessing the summative usability of the device by determining its ease of use, ease of learning and satisfaction among the medical health professionals. The participants will be trained before the study and will be assessed periodically. Each participant will use the device on at least 10 subjects.

Detailed description

A prospective interventional study designed to assess the summative usability and rapidity of CEREBO® - a portable device to detect intracranial haemorrhage. 10 participants from a Primary Health Centre will be enrolled in this study. The participants will be trained by the study staff before the study. The participant will fill in a questionnaire periodically. At the end of the study, the statistical analysis will be performed on the recorded data to establish the ease of use, ease of learning and satisfaction.

Interventions

DEVICECEREBO®

Usability Study

Sponsors

Bioscan Research Pvt. Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Operators * Medical health professionals \>18 years of age with a valid medical license to practice medicine belonging to one of the following categories and have given a written consent to participate in the study. * MBBS * Ayush * Nurse * Others Subjects * Of all ages and gender, have understood the study and gave a written informed consent.

Exclusion criteria

Subjects * Cognitively impaired subjects unable to understand the study procedure

Design outcomes

Primary

MeasureTime frameDescription
To assess the usability of CEREBO® to detect intracranial haemorrhage2 weekA questionnaire filled by the participants will be assessed by the study team to assess the ease of use, ease of learning and satisfaction

Secondary

MeasureTime frameDescription
To assess the rapidity of CEREBO® to detect intracranial haemorrhage2 weekThe time to perform the CEREBO® scan per subject will be determined

Contacts

Primary ContactBioscan Research
info@bioscanresearch.com7948994429

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026